- Home
- GENK vs ALLK Comparison
GENK vs ALLK Comparison
Compare GENK & ALLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENK
- ALLK
- Stock Information
- Founded
- GENK 2011
- ALLK 2012
- Country
- GENK United States
- ALLK United States
- Employees
- GENK N/A
- ALLK N/A
- Industry
- GENK Restaurants
- ALLK Biotechnology: Pharmaceutical Preparations
- Sector
- GENK Consumer Discretionary
- ALLK Health Care
- Exchange
- GENK Nasdaq
- ALLK Nasdaq
- Market Cap
- GENK 27.9M
- ALLK 23.0M
- IPO Year
- GENK 2023
- ALLK 2018
- Fundamental
- Price
- GENK $4.37
- ALLK $0.33
- Analyst Decision
- GENK Strong Buy
- ALLK Hold
- Analyst Count
- GENK 3
- ALLK 3
- Target Price
- GENK $12.17
- ALLK $2.00
- AVG Volume (30 Days)
- GENK 60.3K
- ALLK 2.2M
- Earning Date
- GENK 05-13-2025
- ALLK 05-08-2025
- Dividend Yield
- GENK N/A
- ALLK N/A
- EPS Growth
- GENK 62.05
- ALLK N/A
- EPS
- GENK 0.13
- ALLK N/A
- Revenue
- GENK $208,380,000.00
- ALLK N/A
- Revenue This Year
- GENK $20.48
- ALLK N/A
- Revenue Next Year
- GENK $21.64
- ALLK N/A
- P/E Ratio
- GENK $35.48
- ALLK N/A
- Revenue Growth
- GENK 15.12
- ALLK N/A
- 52 Week Low
- GENK $3.99
- ALLK $0.22
- 52 Week High
- GENK $13.12
- ALLK $1.56
- Technical
- Relative Strength Index (RSI)
- GENK 40.66
- ALLK 60.40
- Support Level
- GENK $3.99
- ALLK $0.31
- Resistance Level
- GENK $4.29
- ALLK $0.33
- Average True Range (ATR)
- GENK 0.43
- ALLK 0.00
- MACD
- GENK 0.01
- ALLK 0.00
- Stochastic Oscillator
- GENK 29.28
- ALLK 78.50
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc is an Asian casual dining restaurant in the United States. It offers an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables.
About ALLK Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation. Its portfolio consists of antibodies that target receptors, particularly Siglec-6, Siglec-8 and other anti-Siglec antibodies, including some antibodies in preclinical development.